This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

10 Mid-Cap Stocks Analysts Love


8. Watson Pharmaceuticals (WPI) manufactures and distributes generic and branded pharmaceutical products. It operates in Asia, Australia, Western Europe, Canada, South America and South Africa, with its commercial market being the U.S.

Thirteen of the 24 analysts covering the stock recommend a buy. There are no sell ratings on the stock. A consensus forecast of analysts polled by Bloomberg has an average 12-month price target of $76.44 for the stock, about 27.5% higher than the current price.

For the third quarter of 2011, Watson reported total revenue of $1.1 billion, up 23% from $882.4 million in the same quarter last year. Adjusted EBITDA rose 22% to $258.2 million, vs. $211.1 million in the third quarter 2010. GAAP diluted earnings per share stood at 54 cents, up from 21 cents in the prior-year quarter. Cash and marketable securities stood at $172.5 million, as of Sept. 30.

In December, Watson Pharmaceuticals and Antares Pharma announced receiving approval from the U.S. Food and Drug Administration for Antares' topical oxybutynin gel 3% for the treatment of an overactive bladder. Same week, under a settlement with Teva Women's Health, Watson launched Amethia Lo (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets, the generic equivalent of birth control medicine LoSeasonique.

For full year 2011, Watson expects total revenue of over $4.5 billion. The company's generic, brand and distribution segments are expected to generate $3.3 billion, $445 million and $770 million, respectively. Non-GAAP diluted earnings per share are expected in the range of $4.55 and $4.65.

3 of 10

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs